Alnylam Pharmaceuticals (ALNY) Competitors $320.87 +3.37 (+1.06%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$326.98 +6.11 (+1.90%) As of 09:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALNY vs. AMGN, GILD, VRTX, REGN, BIIB, INCY, UTHR, NBIX, EXEL, and BMRNShould you be buying Alnylam Pharmaceuticals stock or one of its competitors? The main competitors of Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "biotechnology" industry. Alnylam Pharmaceuticals vs. Its Competitors Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Biogen Incyte United Therapeutics Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Alnylam Pharmaceuticals (NASDAQ:ALNY) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership. Which has more volatility and risk, ALNY or AMGN? Alnylam Pharmaceuticals has a beta of 0.23, indicating that its share price is 77% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Do analysts prefer ALNY or AMGN? Alnylam Pharmaceuticals currently has a consensus price target of $341.91, suggesting a potential upside of 6.56%. Amgen has a consensus price target of $307.82, suggesting a potential upside of 3.81%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Alnylam Pharmaceuticals is more favorable than Amgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.80Amgen 2 Sell rating(s) 12 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.35 Does the media refer more to ALNY or AMGN? In the previous week, Amgen had 32 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 48 mentions for Amgen and 16 mentions for Alnylam Pharmaceuticals. Amgen's average media sentiment score of 1.42 beat Alnylam Pharmaceuticals' score of 0.85 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 9 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amgen 44 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, ALNY or AMGN? Amgen has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.25B18.61-$278.16M-$2.09-153.53Amgen$33.42B4.77$4.09B$10.9627.05 Is ALNY or AMGN more profitable? Amgen has a net margin of 17.39% compared to Alnylam Pharmaceuticals' net margin of -11.49%. Amgen's return on equity of 176.11% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-11.49% -510.31% -6.48% Amgen 17.39%176.11%12.39% Do institutionals and insiders hold more shares of ALNY or AMGN? 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 0.8% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryAmgen beats Alnylam Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALNY vs. The Competition Export to ExcelMetricAlnylam PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.40B$2.90B$5.51B$8.95BDividend YieldN/A2.44%5.25%4.04%P/E Ratio-153.5321.0128.0220.16Price / Sales18.61257.28417.67174.36Price / CashN/A41.8337.0657.97Price / Book617.067.868.145.62Net Income-$278.16M-$54.96M$3.16B$248.50M7 Day Performance-3.33%5.27%3.16%4.49%1 Month Performance6.09%3.78%3.49%7.03%1 Year Performance24.48%5.85%34.22%21.07% Alnylam Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALNYAlnylam Pharmaceuticals4.116 of 5 stars$320.87+1.1%$341.91+6.6%+26.0%$41.40B$2.25B-153.532,230Positive NewsAnalyst ForecastAMGNAmgen4.5364 of 5 stars$279.21+0.8%$307.82+10.2%-6.1%$150.13B$33.42B25.4828,000Positive NewsAnalyst RevisionGILDGilead Sciences4.8336 of 5 stars$110.87+0.2%$110.55-0.3%+67.1%$137.91B$28.74B23.3417,600Trending NewsAnalyst RevisionVRTXVertex Pharmaceuticals4.4527 of 5 stars$445.20+0.9%$511.62+14.9%-1.4%$114.33B$11.02B-113.576,100Positive NewsAnalyst RevisionREGNRegeneron Pharmaceuticals4.9349 of 5 stars$525.00+0.8%$813.57+55.0%-47.6%$56.68B$14.20B13.3711,900Analyst RevisionBIIBBiogen4.9272 of 5 stars$125.59-0.4%$188.48+50.1%-41.9%$18.40B$9.68B12.407,605Positive NewsINCYIncyte4.4367 of 5 stars$68.10-0.4%$74.53+9.4%+13.2%$13.18B$4.24B212.822,617Insider TradeUTHRUnited Therapeutics4.9962 of 5 stars$287.35+1.1%$386.15+34.4%-6.8%$12.96B$2.88B11.471,305Positive NewsAnalyst ForecastNBIXNeurocrine Biosciences4.7678 of 5 stars$125.69+0.2%$162.00+28.9%-6.8%$12.44B$2.36B42.611,800News CoveragePositive NewsAnalyst ForecastInsider TradeEXELExelixis4.7079 of 5 stars$44.08+0.9%$43.56-1.2%+99.0%$12.02B$2.17B20.041,147Analyst ForecastOptions VolumeBMRNBioMarin Pharmaceutical4.9394 of 5 stars$54.97-0.4%$93.45+70.0%-28.1%$10.54B$2.85B20.443,040Positive News Related Companies and Tools Related Companies Amgen Alternatives Gilead Sciences Alternatives Vertex Pharmaceuticals Alternatives Regeneron Pharmaceuticals Alternatives Biogen Alternatives Incyte Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives BioMarin Pharmaceutical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALNY) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALNY Stock Alerts